1. Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
by Shernan G. Holtan, Todd E. DeFor, Angela Panoskaltsis-Mortari, Nandita Khera, John E. Levine, Mary E. D. Flowers, Stephanie J. Lee, Yoshihiro Inamoto, George L. Chen, Sebastian Mayer, Mukta Arora, Jeanne Palmer, Corey S. Cutler, Sally Arai, Aleksandr Lazaryan, Laura F. Newell, Madan H. Jagasia, Iskra Pusic, William A. Wood, Anne S. Renteria, Gregory Yanik, William J. Hogan, Elizabeth Hexner, Francis Ayuk, Ernst Holler, Udomsak Bunworasate, Yvonne A. Efebera, James L. M. Ferrara, Joseph Pidala, Alan Howard, Juan Wu, Javier Bolaños-Meade, Vincent Ho, Amin Alousi, Bruce R. Blazar, Daniel J. Weisdorf, and Margaret L. MacMillan
BloodAdv
Volume 2(15):
August 14, 2018
© 2018 by The American Society of Hematology

2. Shernan G. Holtan et al. Blood Adv 2018;2:1882-1888
© 2018 by The American Society of Hematology

3. Proportion of patients (±95% CI) experiencing clinical end points of day 28 CR/PR, 2-year NRM, and OS by Minnesota GVHD SR vs HR and plasma AREG at the onset of aGVHD.
Proportion of patients (±95% CI) experiencing clinical end points of day 28 CR/PR, 2-year NRM, and OS by Minnesota GVHD SR vs HR and plasma AREG at the onset of aGVHD.
Shernan G. Holtan et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Patients enrolled in BMT CTN 0302/0802 by AREG plus Minnesota risk score group.
Patients enrolled in BMT CTN 0302/0802 by AREG plus Minnesota risk score group. (A) OS and (B) NRM.
Shernan G. Holtan et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology